Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase II randomised, double-blind, parallel group study investigating NEPA (netupitant/palonosetron) in chemotherapy-naive patients undergoing cisplatin-based highly emetogenic chemotherapy

Next Previous
Trial Profile

Pivotal phase II randomised, double-blind, parallel group study investigating NEPA (netupitant/palonosetron) in chemotherapy-naive patients undergoing cisplatin-based highly emetogenic chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary) ; Aprepitant; Dexamethasone; Ondansetron; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 08 May 2015 According to a Specialised Therapeutics Australia media release, Akynzeo was approved by the Therapeutics Goods Agency (TGA) for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. The approval was based on results from this and other III trials (see profile 700201211 and 70056856).
    • 30 Mar 2015 According to Helsinn media release, European Medicines Agency (EMA) has adopted a positive opinion about netupitant/palonestron [AKYNZEO] approval for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy, recommended by Committee for Medicinal Products for Human Use (CHMP). The opinion was based on data from this and other phase II and III trials.
    • 13 Oct 2014 The US FDA approved AKYNZEO for the prevention of CINV based on data from this study and 2 phase III trials, according to a media release from Helsinn and Eisai.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top